< Back to topics
> Cover Page, Authors, Institutions
> View tables/images/videos
Forty-nine eligible patients with pathologically confirmed Stage III NSCLC were enrolled between December of 2003 and August of 2005. Eighteen patients had stage IIIA and 31 patients had stage IIIB disease. Daily fractions of 2.4 Gy and 1.8 Gy were delivered to GTV and CTV to a total dose of 60 Gy and 45 Gy in 25 fractions over 5 weeks, respectively, by using 3D-conformal radiotherapy techniques. All patients received concurrent weekly chemotherapy consisted of Paclitaxel (50 mg/m2 iv over 1 hour, days 1, 8, 15, 22, 29, 36) and Carboplatin (AUC=2, iv over 30 minutes, days 1, 8, 15, 22, 29, 36).
Click on images to enlarge (a new pop-up window will open)